Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment, while avoiding the systemic immunosuppression of conventional medicines. The company's proprietary technology platform enables the design of bispecific antibodies with targeting fragments that bind to specific tissues at the local site of inflammatory disease, coupled with effector molecules that modulate immune activity to restore immune homeostasis.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/18/18 | $58,000,000 | Series A |
Polaris Partners Roche Venture Fund SR One Versant Ventures | undisclosed |
| 04/01/20 | $80,000,000 | Series B |
Access Industries Boxer Capital JDRF T1D Fund OrbiMed Advisors Polaris Partners RA Capital Roche Venture Fund SR One Versant Ventures | undisclosed |
